PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.02 | $0 | -$784,272 |
| 2025 Q4 | 8.58 | $0 | -$933,544 |
| 2025 Q3 | -0.03 | $0 | -$1M |
| 2025 Q2 | -1.29 | $0 | -$3M |
| 2025 Q1 | -9.37 | $0 | -$2M |
| 2024 Q4 | -0.13 | $725,403 | $959,956 |
| 2024 Q3 | -1.15 | $2M | -$790,384 |
| 2024 Q2 | -0.37 | $1M | -$2M |